Member Info for Soupdragon78

Shandypants, nfx have 20k per month income at the moment as well as the 400k at end of September.

The ‘270k’ was Oxilio placing to value themselves at £254m

Oxilio trials are not on the NXP001 aspect, they are still working on formulation of that.

My thoughts are that they will be doing the clinical trials on their own drug first, raising money off the back of that before pushing the NXP001 cocrystal forward. (They only raised £270k in august so likely don't have the funds to push the two forward at the same time)

I'm sure when she's sat by the fire remembering the time her shares were worth £5m quid, she'll be thinking 'I haven't lost anything.'

FX, you said she didn't pay for them, so she would be averaging up if she bought any. Her average is zero.

With the change in the auditing rules, its pretty much just the big four who provide the required service as the smaller auditors would be required to firstly get registered to do PIE's, then they need to register their Responsible Individuals to be able to do the audit. Hence Jefferies pulled out of the market.

'In 2021, the Big Four audit the majority of PIE clients, with PwC auditing 424 PIE audits, KPMG 279, EY 262 and Deloitte 302, according to the FRC data. Among the mid-tier and smaller firms, many, including Haines Watts, Watson Buckle and BSG Valentine, had just one PIE audit each.'

I guess when she watch her share value drop from £5m to £100k she might have sought solace that she was in the same boat as us here on the forum.

Fx, yes they both didn’t pay for their shares. But if this doesn’t go anywhere then they are worthless so doesn’t matter anyway.

The point is you point to DG saying he will profit from nxp001 anyway, yet JH doesn’t have that luxury, so why would she have kept her holding if she didn’t have faith?

FX, and what about Jo Holland then?

Yep, just passing the time whilst we wait.

"The European Respiratory Society (ERS) meeting took place in September in Barcelona, and was a great occasion to review respiratory drug development, hear about recent clinical trial results, and discuss exciting new translational science in the poster sessions. We were delighted to be able to support one of our clients in presenting their data at the event. It was great to attend several talks highlighting the benefits of inhaled drugs for respiratory disease as this is an approach that we think can be extremely valuable."

https://therapeutaix.com/2022-a-therapeutaix-roundup/

Wonder what Riddell got in return for delivering the company to Stanford?
He clearly wasn’t up to the job. Poor old chap, now has to spend his time dealing with stationary supplies for a startup.

Always a classic.

Mulderoutthere
Posted in: NFX
Posts: 202
Price: 0.90
No Opinion
RE: Lynparza in the press22 Mar 2022 13:14
? Is no talking down company - just reply you lynparza idea

I miss foremagnus, although posting under two usernames was actually misleading (not verging on…)

First week back is always going to be quiet. Just a few folk trying to make themselves feel better by having a bit of a moan.

Happy New Year to all, hope everyone is well rested and had a great time with family and friends.

Lanstead keeping on selling, no surprise there.

Nice to have a quiet day for once.

Anyway, all the best for Xmas to everyone here no matter what your persuasion.

I’ll take that as a yes

Take it you’ve sold now blood?

NFTs, firstly you need to look up what outlicensing actually means and how it works.

Secondly you say that NXP002 data is late.

Dan literally told you at the beginning of November it would be q1 2023.

Is a placing the only means of raising funds open to the company?